Overview
Pancreatic ascites is a rare complication characterized by the accumulation of fluid in the peritoneal cavity, often associated with pancreatic duct disruption or leakage, leading to significant morbidity 35.Diagnosis
Clinical Presentation: Presence of ascites with potential signs of portal hypertension or malignancy 2.
Laboratory Tests: Analyze ascitic fluid for cell count, protein levels, and tumor markers (CEA, CA125, CA 19-9) to differentiate between malignant and tuberculous causes 2.
Imaging: Ultrasonography to confirm ascites and rule out other intra-abdominal masses 8.
Differential Diagnosis: Distinguish from other causes like peritoneal dialysis-related ascites, hemodialysis complications, and non-pancreatic etiologies 456.Management
First-Line Treatments:
- Surgical Intervention: Repair of pancreatic duct leak or resection if feasible 3.
- Peritoneovenous Shunt: For intractable ascites, though associated with risks like disseminated intravascular coagulation 37.
Adjunctive Therapies:
- Peritoneal Dialysis: Effective in managing dialysis-induced ascites 4.
- Isolated Ultrafiltration: Consider as a noninvasive initial treatment option 6.
- Dietary Management: Strict fluid and sodium restriction 4.Special Populations
Comorbidities: Patients with end-stage renal disease may experience dialysis-related ascites requiring tailored management approaches 456.
Elderly: Increased susceptibility to complications from invasive procedures like peritoneovenous shunts 7.Key Recommendations
Utilize ascitic fluid analysis, including tumor markers and protein ratios, for differentiating malignant from tuberculous ascites (Evidence: Moderate 2).
Consider isolated ultrafiltration as a first-line, noninvasive treatment for dialysis-induced ascites (Evidence: Weak 6).
Evaluate the use of peritoneovenous shunts cautiously due to potential severe complications like disseminated intravascular coagulation (Evidence: Weak 7).
Tailor management strategies in elderly patients and those with end-stage renal disease, considering the risks and benefits of invasive procedures (Evidence: Expert opinion).References
1 Ivady G, Barath S, Szaraz-Szeles M, Szabo EK, Kovacs K, Petruska E et al.. Comparative Evaluation of Body Fluid Analysis by Sysmex XN Hematology Analyzers, CellaVision, Manual Microscopy and Multicolor Flow Cytometry. Annals of clinical and laboratory science 2022. link
2 Yu T, Shu L, Chen Y, Zhu Y, Lu N, Lai Y et al.. Diagnosis of malignant versus tuberculous ascites using tumor markers and globulin ratios in serum and ascites: A Fisher discriminant model. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology 2021. link
3 Utíkal P, Drác P, Bachleda P, Klein J, Král V, Hrabalová M. Peritoneovenous shunt - modification with the use of long saphenous vein. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2004. link
4 Bennett RR, Moore J. Dialysis-induced ascites treated with peritoneal dialysis. Southern medical journal 1987. link
5 Popli S, Chen WT, Nakamoto S, Daugirdas JT, Cespedes LE, Ing TS. Hemodialysis ascites in anephric patients. Clinical nephrology 1981. link
6 Shin KD, Ing TS, Popli S, Daugirdas JT, Ghantous WN, Vilbar RM et al.. Isolated ultrafiltration in the treatment of dialysis ascites. Artificial organs 1979. link
7 Matseshe JW, Beart RW, Bartholomew LG, Baldus WP. Fatal disseminated intravascular coagulation after peritoneovenous shunt for intractable ascites. Mayo Clinic proceedings 1978. link
8 Yeh HC, Wolf BS. Ultrasonography in ascites. Radiology 1977. link